MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.16 5.45

Buy Sell

Overview

Share price change

24h

Current

Min

1.1

Max

1.16

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+321.82% upside

Dividends
By Dow Jones
Next Earnings	3 mar 2026

Market Stats
By TradingEconomics
Market Cap	12M 137M
Previous open	-4.29
Previous close	1.16

News Sentiment

By Acuity

67%

33%

325 / 360 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

21 sty 2026, 23:49 UTC

Major Market Movers

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 sty 2026, 21:12 UTC

Major Market Movers

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 sty 2026, 21:00 UTC

Acquisitions, Mergers, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 sty 2026, 20:29 UTC

Major Market Movers

Chip Makers Gain After Trump Calls Off European Tariffs

21 sty 2026, 20:04 UTC

Major Market Movers

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 sty 2026, 23:48 UTC

Market Talk

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 sty 2026, 23:34 UTC

Market Talk

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 sty 2026, 22:39 UTC

Earnings

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 sty 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

21 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 sty 2026, 21:35 UTC

Acquisitions, Mergers, Takeovers

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 sty 2026, 21:19 UTC

Earnings

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 sty 2026, 20:45 UTC

Acquisitions, Mergers, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 sty 2026, 20:36 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 sty 2026, 20:31 UTC

Market Talk

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 sty 2026, 20:27 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 sty 2026, 20:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 sty 2026, 20:27 UTC

Market Talk

Was It a 'TACO' Event? -- Market Talk

21 sty 2026, 20:26 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 sty 2026, 20:23 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 sty 2026, 20:21 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 sty 2026, 20:19 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse Group Agrees to Buy Allfunds

21 sty 2026, 20:08 UTC

Earnings

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 sty 2026, 20:03 UTC

Market Talk

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 sty 2026, 19:51 UTC

Market Talk

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 sty 2026, 19:43 UTC

Market Talk

U.S. Ethanol Production Expected to Slip -- Market Talk

21 sty 2026, 19:31 UTC

Market Talk

Gold Settles at Fresh All-Time High -- Market Talk

21 sty 2026, 19:24 UTC

Earnings

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 sty 2026, 19:10 UTC

Market Talk

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 sty 2026, 18:57 UTC

Market Talk

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

321.82% upside

12 Months Forecast

Average 4.64 USD 321.82%

High 8 USD

Low 2 USD

Based on 9 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

325 / 360 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.